Pfizer is buying Toronto and Cambridge, Massachusetts-based Trillium Therapeutics in a deal worth $2.26 billion. Trillium focuses on developing a new set of checkpoint inhibitors to treat cancer.

GlaxoSmithKline’s entire stake in Innoviva was sold back to the U.S.-based biopharmaceutical company for about $392 million, the British drugmaker said on May 20, as GSK simplifies operations ahead of a split into two businesses.

Sanofi SA said the company would sell its stake in Regeneron Pharmaceuticals Inc., but would not change their ongoing collaboration.

Bristol-Myers Squibb and Israel’s Compugen will collaborate in clinical trials for patients with advanced solid tumors.

Pershing Square, a hedge fund run by activist investor William Ackman, and Valeant decided to settle an insider trading lawsuit with Allergan and pay $290 million.

A filing with the U.S. Securities and Exchange Commission (SEC) indicates that the UK’s GlaxoSmithKline has a 13 percent stake in Spero Therapeutics, with 1,854,006 shares in the Massachusetts biotech company.

Basel, Switzerland-based Novartis has decided not to sell its $14 billion stake in Swiss rival Roche.